Invalidity dossier
US 7704510
Cytomegalovirus surface protein complex for use in vaccines and as a drug target
Current assignee: Princeton University
Added 9/21/2026, 10:33:24 AM
Active provider: DeepSeek · deepseek-flash
Patent summary
Title, assignee, inventors, filing/issue dates, abstract, and a plain-language overview of the claims.
Patent Overview: US7704510B2
Title: Cytomegalovirus surface protein complex for use in vaccines and as a drug target
Patent number: US7704510B2 | Application: US11/810,578 | Publication: US20080187545A1
Inventors: Thomas Shenk; Dai Wang
Assignee: Princeton University (original and current, per the listing)
Key dates: Priority date 2006-06-07; filing date 2007-06-06; granted/publication date 2010-04-27; anticipated expiration 2027-06-06. Legal status listed as Active.
Purpose (per the supplied text): The invention "relates generally to the fields of vaccine development, passive immunity and antiviral drug discovery." More specifically, it concerns vaccines against cytomegalovirus (CMV), antibodies as therapeutic agents for treating CMV infections, and screening assays to identify molecules that inhibit CMV infectivity.
Plain-language scope from the excerpt: CMV is a herpes virus (betaherpesviridae) infecting an estimated 40–80% of US adults, spread mainly through bodily fluids, and a leading cause of birth defects; no cure or preventive vaccine exists. CMV particles carry three major glycoprotein complexes required for infectivity: gCI (gB/UL55), gCII (gM/UL100 and gN/UL73), and gCIII (gH/UL75, gL/UL115, gO/UL74). The excerpt notes that proteins encoded by UL131–UL128 "heretofore have not been reported to" (sentence truncated in the supplied text). The prior-art keywords listed are CMV, pUL128, pUL130, complex, and antibodies. Classifications include viral antigens (A61K39/245), CMV antibodies (C07K16/089), and drug-screening methods (C12Q1/025). The record also notes first worldwide family litigation and an NIH confirmatory license, and lists several later priority-linked US applications.
What the excerpt does not establish: It does not provide the claims, detailed description, examples, or the complete sentence regarding UL131–UL128. It does not establish the specific pUL128/pUL130 complex composition, vaccine formulations, or assay steps. It does not establish validity, enforceability, claim scope, or prior-art effect; litigation, ownership, and prior-art analysis were excluded per instruction.
Source: https://patents.google.com/patent/[US7704510](/patent/US7704510)/en
Generated 10/1/2026, 10:01:27 PM
Cases on file (0)
Specific litigation cases in our database that name US patent 7704510. The free-form analysis below may also discuss cases beyond this list.
No cases on file mention this patent. Upload a CSV or add a case manually in Admin → Manage litigation cases.
Litigation summary
Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.
Proceedings on file (0)
All PTAB activity →AIA trial proceedings (IPR / PGR / CBM) filed at the USPTO Patent Trial and Appeal Board against this patent. Sourced from the USPTO Open Data Portal and refreshed every six hours; each proceeding number deep-links to the PTAB E2E docket.
No PTAB proceedings on file. This patent has not been challenged via IPR, PGR, or CBM. The absence is itself a signal — well-asserted patents eventually attract IPRs. The LLM analysis below may surface filings the ODP feed hasn’t indexed yet.
PTAB challenges
AIA trial proceedings at the USPTO Patent Trial and Appeal Board — IPR, PGR, and CBM. Petitioners, judge panels, claim-level invalidation outcomes from Final Written Decisions, and Federal Circuit appeals. The single most important defensive datapoint after litigation history.
Assignment history
Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.
Prior art
Earlier patents, publications, and products that may anticipate or render the claims unpatentable.
Obviousness
Combinations of prior art that suggest the claimed invention would have been obvious under 35 U.S.C. § 103.
Extensions
Patent term adjustments, term extensions, continuations, divisionals, family members, and expiration dates.
Derivative works
Defensive disclosure: derivative variations of each claim designed to render future incremental improvements obvious or non-novel.